Innate Pharma IPHA
NASDAQ IPHA
$1.58 +0.10 (+7.01%)
As of: Oct 20, 2026 · 3:59 PM EDT

Innate Pharma (IPHA) Research & Development (2019)

Updated

Innate Pharma's Research & Development was -$19.62 million in the quarter ended Jun 30, 2026, compared with -$23.23 million a year earlier.

Analysis

Innate Pharma (IPHA) Research & Development (2019) Analysis & Trends

On a trailing twelve-month basis, Innate Pharma's Research & Development was -$149.17 million through Jun 30, 2026; for the year ended Dec 31, 2025, it was -$49.28 million.

  • In earlier years, Research & Development was -$56.26 million in the year ended Dec 31, 2024, -$60.6 million in the year ended Dec 31, 2023, -$54.45 million in the year ended Dec 31, 2022 and -$53.77 million in the year ended Dec 31, 2021.
  • The figure for the quarter ended Jun 30, 2026 marks the highest quarterly Research & Development in data going back to the quarter ended Jun 30, 2019.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) R&D (Qtr)
1 Eli Lilly 1,146.94 Bn 1,115.53 Bn 19.71 Bn 3.82 Bn
2 Johnson & Johnson 624.96 Bn 543.49 Bn 17.26 Bn 3.65 Bn
3 AbbVie 510.15 Bn 483.27 Bn 12.70 Bn 2.34 Bn
4 Merck 366.13 Bn 320.51 Bn 12.21 Bn 9.74 Bn
5 Novartis Ag 297.75 Bn 261.74 Bn 11.24 Bn 2.85 Bn
6 Astrazeneca 261.93 Bn 235.62 Bn 12.86 Bn 4.05 Bn
7 Amgen 236.51 Bn 191.91 Bn 7.24 Bn 1.87 Bn
8 Gilead Sciences 194.27 Bn 168.47 Bn 6.22 Bn 1.76 Bn
9 Pfizer 171.74 Bn 118.39 Bn 10.94 Bn 2.81 Bn
10 Innate Pharma 142.45 Mn -64.75 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2019 -41.11 Mn
API Access

Innate Pharma Research & Development API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=research-and-development&ticker=IPHA&period=max&api_key=YOUR_API_KEY